Can you have sexual intercourse while receiving subcutaneous injections?

Sep 27, 2023 Source: Cainiu Health
Dr. Liu Qingyun
Introduction
In general, whether sexual intercourse is allowed while receiving abdominal injections should be determined based on the patient's specific medical condition. For patients undergoing in vitro fertilization (IVF), sexual intercourse is typically not recommended. However, for patients with breast cancer, it is usually permissible. Patients should consult a healthcare professional regarding whether sexual activity is safe after abdominal injections. If any discomfort or adverse symptoms occur, prompt medical attention at a hospital is advised to avoid delaying treatment.

In general, whether sexual intercourse is allowed during subcutaneous injections (commonly referred to as "belly shots") depends on the patient's specific medical condition. For patients undergoing in vitro fertilization (IVF), sexual intercourse is typically not recommended; however, for patients with breast cancer, it is usually permissible. The details are as follows:

1. Not recommended

If the patient is receiving subcutaneous injections for IVF treatment, sexual intercourse is generally not advised during the medication period. On one hand, once the injections reach the ovulation induction phase—when daily injections begin—it usually takes about 10 days before egg retrieval, which is performed vaginally. Sexual intercourse may increase the risk of infection during egg retrieval. Therefore, once a patient enters the subcutaneous injection phase of IVF, abstaining from sex is recommended to reduce the risk of post-retrieval infections. Additionally, during IVF treatment, hormonal medications cause multiple follicles to develop within the ovaries, leading to ovarian enlargement. Due to this enlargement, sexual activity could potentially trigger ovarian torsion. If not promptly treated, ovarian torsion may lead to tissue necrosis and render the follicles unusable, posing a serious health risk.

2. Permissible

If the subcutaneous injection is a luteinizing hormone-releasing hormone (LHRH) agonist administered to a breast cancer patient, it typically does not affect sexual activity. LHRH agonists are used in treating metastatic or early-stage breast cancer, as well as conditions like precocious puberty. These medications generally do not harm the body or impair sexual function. Therefore, breast cancer patients receiving LHRH agonist injections can usually continue having sexual intercourse without concern.

Patients should consult their healthcare provider regarding whether sexual intercourse is safe after receiving subcutaneous injections. If any discomfort occurs, prompt medical evaluation at a hospital is recommended to avoid delays in diagnosis or treatment.

Related Articles

View All